About Matrix Biomed, Inc.
We are a biopharmaceutical company dedicated to the development of novel gene-based therapeutics to treat and prevent severe, often life-threatening, diseases and conditions for which treatments are not currently available.
-
Tempol may well be the most important therapeutic breakthrough in over 50 years. It holds promise to substantially reduce health care costs and improve treatment of a wide array of diseases."
Chief of Division of Nephrology and Hypertension, Director of the Hypertension Kidney and Vascular Research Center, and Associate Director of the Angiogensis Program in the Lombardi Cancer Institute
-
"Tempol holds enormous promise as a treatment for CD and UC. As noted by the research, Tempol may not only be beneficial, but a novel approach to the treatment and prevention of IBD and other conditions associated with the local or systemic inflammation."
Professor and Chief, Gastroenterology; Executive Director, Comprehensive Digestive Disease Center, Endowed Chair, Endoscopy Oncology, University of California, Irvine
